Latest / DDReg Knowledge Capsule
Global Biosimilar Pathways 2026 : US, EU, UK & Asia
Welcome to the DDReg Knowledge Capsule!
In this episode, we unpack the rapidly changing global regulatory landscape for biosimilar development across key target markets: the US (FDA), European Union (EMA), UK (MHRA), China (NMPA/CDE), and Japan (PMDA).We examine the pivotal 2026 transition away from routine comparative clinical efficacy trials toward tailored, risk-based evaluation frameworks grounded in high-resolution comparative analytical data, pharmacokinetic (PK) studies, and immunogenicity assessments.Key topics covered in this episode:
Tailored Evidence Pathways: How regulators like…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.